trending Market Intelligence /marketintelligence/en/news-insights/trending/4jP1g6qbHUxyeuYtVAxS1A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Millendo Therapeutics prices $25M offering to fund product candidates

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Millendo Therapeutics prices $25M offering to fund product candidates

Millendo Therapeutics Inc. priced its offering of 4,166,667 common shares at $6 each.

The Ann Arbor, Mich.-based biopharmaceutical company granted underwriters a 30-day option to buy up to an additional 625,000 common shares at the same price.

Gross proceeds are expected to be about $25 million.

The offering is expected to close Dec. 9. Proceeds will be used to develop product candidates in its pipeline and for working capital, capital expenditures and general corporate purposes.

Citigroup and SVB Leerink are acting as joint book-running managers for the offer.

Millendo Therapeutics develops medicines for orphan endocrine diseases.